SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending following a significant legal victory where the SEC closed its investigation into the company without charges, fueling optimism among investors about its regulatory standing in the real-world asset (RWA) sector. Community sentiment is deeply divided, with bulls highlighting the project's institutional partnerships and potential for mass tokenization, while others remain frustrated by persistent price stagnation, upcoming token unlocks, and concerns over heavy circulating supply.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to reports of early-stage research into an mRNA vaccine targeting Hantavirus, fueling speculation about potential pandemic-related demand. The community is actively debating the company's long-term mRNA platform pipeline, the potential for a short squeeze, and the implications of renewed interest in biosecurity and vaccine development.

Hormel Foods Corp. engages in the manufacturing and marketing of branded food products. It operates through the following segments: Retail, Foodservice, and International. The Retail segment consists of the processing, marketing, and sale of food products sold predominantly in the retail market. The Foodservice segment includes the processing, marketing, and sale of food and nutritional products for foodservice, convenience store, and commercial customers. The International segment focuses on processing, marketing, and selling company products internationally. The company was founded by George A. Hormel in 1891 and is headquartered in Austin, MN.

Hormel Foods Corp.

Hormel Foods is trending as investors weigh its defensive status and dividend yield against significant margin pressures caused by volatile commodity costs and production challenges. The community is actively debating the stock's long-term value at current levels, with many focusing on whether these headwinds represent a buying opportunity for a dividend aristocrat or a sign of deeper operational struggles.

Conagra Brands, Inc. engages in the manufacture and sale of processed and packaged foods. It operates through the following segments: Grocery and Snacks, Refrigerated and Frozen, International, and Foodservice. The Grocery and Snacks segment includes branded, and shelf stable food products sold in various retail channels in the United States. The Refrigerated and Frozen segment is composed of branded, and temperature-controlled food products sold in various retail channels in the United States. The International segment offers branded food products in various temperature states, sold in various retail and foodservice channels outside of the United States. The Foodservice segment focuses on branded and customized food products, including meals, entrees, sauces, and a variety of custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The company was founded by Alva Kinney and Frank Little in 1919 and is headquartered in Chicago, IL.

Conagra Brands Inc

Conagra Brands (CAG) is trending as investors weigh its attractive near-double-digit dividend yield against concerns about persistent margin pressure and shifting consumer demand toward private-label products. While some community members view the stock as an undervalued income play near generational lows, others remain cautious, highlighting the impact of GLP-1 medications on snack consumption and potential risks to dividend sustainability.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as investors weigh a new CEO-led strategic pivot against persistent concerns regarding private-label competition and debt. The community is actively debating the stock's potential as a "quality at a discount" turnaround play, supported by an attractive dividend yield and persistent speculation regarding potential M&A activity within the broader packaged food sector.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The S&P 500 is experiencing heightened volatility as investors weigh resilient corporate earnings and AI-driven growth against ongoing geopolitical instability in the Middle East. While many retail investors continue to favor VOO as a core long-term vehicle for dollar-cost averaging, community sentiment remains divided between those betting on market resilience and those anticipating deeper pullbacks amid concerns over potential energy supply shocks and broader economic uncertainty.

Willow Lane Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 3, 2024 and is headquartered in New York, NY.

Willow Lane Acquisition Corp. - Ordinary Shares - Class A

Willow Lane Acquisition Corp. is trending as investors focus on its upcoming merger with Boost Run, an AI infrastructure provider that recently secured a major hardware agreement with Dell Technologies. Community discussion is centered on the company's high growth projections, its NVIDIA-certified cloud status, and the potential for a significant stock price movement following the transition to the new ticker symbol $BRUN.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is trending as investors debate Cathie Wood's ongoing aggressive buying strategy, particularly her recent focus on AI-adjacent assets and retail fintech platforms like Robinhood. Market sentiment remains polarized, with some community members viewing these reallocations as high-conviction plays during market rotation, while skeptics point to historical performance and fund outflows as reasons for caution.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as a primary proxy for SpaceX exposure, with investors focused on the company's significant equity stake and spectrum deals as catalysts for potential value realization ahead of a highly anticipated IPO. Community discussion is dominated by debates over valuation relative to net asset value, speculation regarding potential mergers or acquisitions, and strategic positioning to capture upside from upcoming space sector milestones.

DoubleDown Interactive Co., Ltd. engages in the gaming entertainment business. It operates through the Gaming and iGaming business divisions. The Gaming business division develops and publishes social casinos and casual games. The iGaming business division refers to development and operation of license-based online casinos. The company was founded in December 2007 and is headquartered in Seoul, South Korea.

DoubleDown Interactive Co Ltd - ADR

DoubleDown Interactive Co.

DoubleDown Interactive is drawing attention as shareholders debate the merits of a buyout proposal, with many community members arguing the offer price significantly undervalues the company's strong cash position and growth potential. Investors are actively discussing the role of its major shareholders and management's capital allocation strategy, leading to varied sentiment on whether to push for a higher valuation or remain cautious about the deal's approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Still a Buy?

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's Why...

Alpha Tau Medical (NASDAQ:DRTS) Reaches New 1-Year High - Time to Buy?

Alpha Tau Medical (NASDAQ:DRTS) Hits New 52-Week High - Here's Why...

Alpha Tau Medical (NASDAQ:DRTS) Sees Strong Trading Volume - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Sees Large Volume Increase - Here's Why...

Alpha Tau Medical (NASDAQ:DRTS) Trading Up 13.6% - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Trading 13.6% Higher - Here's What Happened...

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The main goal of the study is to evaluate safety, feasibility, and tolerability, track tumor response, disease progression, and survival outcomes</li><li>The biotech firm also marked the debut of its Alpha DaRT therapy for pancreatic cancer in Europe.</li></ul>Shares of Alpha Tau Medical (DRTS) drew strong retail attention on Friday, rising nearly 4% in pre-market trading after the company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.On Thursday, the U.S. Food and Drug Administration (FDA) cleared an Investigational Device Exemption (IDE) supplement to expand its pancreatic cancer study, known as the IMPACT trial, which is testing its Alpha DaRT therapy alongside chemotherapy.The update allows the company to enroll 10 additional patients receiving the chemotherapy combination Gemcitabine and Abraxane, split evenly between locally advanced and metastatic pancreatic cancer cases. This expansion takes the total enrollment to 40 patients.The IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma. The main goal of the study is to evaluate safety, feasibility, and tolerability, while also tracking tumor response, disease progression, survival outcomes, and patient-reported pain relief.<h2 class="st-heading-2">Retail Bullish On Trial Expansion</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/DRTS">DRTS</a> on Stocktwits turned ‘bullish’ from ‘neutral,’ a day earlier, amid ‘high’ message volumes. Chatter on the platform was up by 200% over the past 24 hours.One user said the trial expansion wouldn’t have taken place if the “safety profile wasn’t looking solid.”<stembedurl>https://stocktwits.com/mattstk2000/message/651253093</stembedurl>Another user was bullish on the company’s prospects for treating pancreatic cancer.<stembedurl>https://stocktwits.com/Pristine_Hurry/message/651252964</stembedurl><h2 class="st-heading-2">Treats First Patient In Europe</h2>Alpha Tau Medical also said it treated the first patient in its ACAPELLA trial, marking the debut of its Alpha DaRT therapy for pancreatic cancer in Europe. The study is testing Alpha DaRT alongside Capecitabine in patients with inoperable, locally advanced disease who have already completed standard chemotherapy.Management said the trial targets a major care gap, as there is currently no standard follow-up treatment for such patients. Pancreatic cancer remains highly lethal, with about 30% of Europe’s 140,000 annual cases diagnosed at this stage.“Over forty thousand Europeans each year are diagnosed with inoperable locally advanced pancreatic cancer, and even if there are some patients who have managed to complete first-line chemotherapy, there remains no established next step, no standard treatment path, and an inevitable progression for the great majority. That is the great unmet need ACAPELLA was designed to address,” CEO Uzi Sofer said.DRTS shares have surged more than 57% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion

The company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.

DRTS Is Back On Retail Radar: These Two Catalysts Are Driving The Rally

Equity

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat...

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 771,223...

Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS

Apella Capital LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2%  - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2% - Still a Buy...

Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS

Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F...

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

DRTS
ALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest DRTS News

DRTSALPHA TAU MEDICAL LTD